Teva Pharmaceutical Industries Limited (NYSE: TEVA) Stock Competitors & Peer Comparison
See TEVA's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TEVA and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TEVA | $35.36 | +1.58% | 41.2B | 12.06 | $2.93 | N/A |
| TAK | $17.45 | +2.53% | 55.5B | 12.55 | $1.39 | +3.61% |
| HLN | $10.03 | +0.00% | 44.2B | 25.11 | $0.40 | +1.76% |
| VTRS | $16.43 | +0.86% | 19.1B | 6.52 | $2.52 | +2.90% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.12 | -8.60% | 11B | 20.86 | $1.06 | N/A |
| RDY | $12.22 | +0.91% | 10.2B | 20.01 | $0.61 | +0.68% |
| LNTH | $100.95 | -0.12% | 6.6B | 16.97 | $5.95 | N/A |
| AMRX | $18.14 | +0.39% | 5.8B | 20.16 | $0.90 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
TEVA vs TAK Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while TAK trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas TAK's P/E ratio is 12.55. In terms of profitability, TEVA's ROE is +0.09%, compared to TAK's ROE of +0.02%. Regarding short-term risk, TEVA is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check TAK's competition here
Haleon plc (NYSE: HLN)
TEVA vs HLN Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while HLN trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas HLN's P/E ratio is 25.11. In terms of profitability, TEVA's ROE is +0.09%, compared to HLN's ROE of +0.17%. Regarding short-term risk, TEVA is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check HLN's competition here
Viatris Inc. (NASDAQ: VTRS)
TEVA vs VTRS Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while VTRS trades at $16.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas VTRS's P/E ratio is 6.52. In terms of profitability, TEVA's ROE is +0.09%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TEVA is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
TEVA vs ITCI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TEVA's ROE is +0.09%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TEVA is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
TEVA vs CTLT Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TEVA's ROE is +0.09%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TEVA is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
TEVA vs ELAN Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ELAN trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ELAN's P/E ratio is 20.86. In terms of profitability, TEVA's ROE is +0.09%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, TEVA is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
TEVA vs RDY Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while RDY trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas RDY's P/E ratio is 20.01. In terms of profitability, TEVA's ROE is +0.09%, compared to RDY's ROE of +0.09%. Regarding short-term risk, TEVA is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
TEVA vs LNTH Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while LNTH trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas LNTH's P/E ratio is 16.97. In terms of profitability, TEVA's ROE is +0.09%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TEVA is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
TEVA vs AMRX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while AMRX trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas AMRX's P/E ratio is 20.16. In terms of profitability, TEVA's ROE is +0.09%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, TEVA is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
TEVA vs INDV Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while INDV trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas INDV's P/E ratio is 10.64. In terms of profitability, TEVA's ROE is +0.09%, compared to INDV's ROE of -2.16%. Regarding short-term risk, TEVA is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
TEVA vs SUPN Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while SUPN trades at $47.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas SUPN's P/E ratio is 15.57. In terms of profitability, TEVA's ROE is +0.09%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, TEVA is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
TEVA vs RGC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas RGC's P/E ratio is -380.99. In terms of profitability, TEVA's ROE is +0.09%, compared to RGC's ROE of -2.32%. Regarding short-term risk, TEVA is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
TEVA vs BHC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while BHC trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas BHC's P/E ratio is 1.59. In terms of profitability, TEVA's ROE is +0.09%, compared to BHC's ROE of +0.89%. Regarding short-term risk, TEVA is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
TEVA vs DCPH Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TEVA's ROE is +0.09%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TEVA is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
TEVA vs HCM Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while HCM trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas HCM's P/E ratio is 4.69. In terms of profitability, TEVA's ROE is +0.09%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TEVA is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
TEVA vs AVDL Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TEVA's ROE is +0.09%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, TEVA is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
TEVA vs EMBCV Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TEVA's ROE is +0.09%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TEVA is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
TEVA vs DVAX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TEVA's ROE is +0.09%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, TEVA is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
TEVA vs ANIP Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ANIP trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ANIP's P/E ratio is 9.52. In terms of profitability, TEVA's ROE is +0.09%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, TEVA is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ANIP's competition here
Perrigo Company plc (NYSE: PRGO)
TEVA vs PRGO Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while PRGO trades at $12.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas PRGO's P/E ratio is 5.13. In terms of profitability, TEVA's ROE is +0.09%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, TEVA is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PRGO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
TEVA vs TARO Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas TARO's P/E ratio is 30.05. In terms of profitability, TEVA's ROE is +0.09%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TEVA is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
TEVA vs HROW Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while HROW trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas HROW's P/E ratio is 449.33. In terms of profitability, TEVA's ROE is +0.09%, compared to HROW's ROE of -0.34%. Regarding short-term risk, TEVA is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
TEVA vs PAHC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while PAHC trades at $34.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas PAHC's P/E ratio is 11.70. In terms of profitability, TEVA's ROE is +0.09%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TEVA is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
TEVA vs ALVO Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ALVO trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ALVO's P/E ratio is -11.21. In terms of profitability, TEVA's ROE is +0.09%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, TEVA is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
TEVA vs ETON Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ETON trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ETON's P/E ratio is -637.14. In terms of profitability, TEVA's ROE is +0.09%, compared to ETON's ROE of -0.06%. Regarding short-term risk, TEVA is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
TEVA vs CRON Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while CRON trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas CRON's P/E ratio is 29.44. In terms of profitability, TEVA's ROE is +0.09%, compared to CRON's ROE of +0.06%. Regarding short-term risk, TEVA is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
TEVA vs PCRX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while PCRX trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas PCRX's P/E ratio is 9.62. In terms of profitability, TEVA's ROE is +0.09%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, TEVA is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PCRX's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
TEVA vs COLL Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while COLL trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas COLL's P/E ratio is 3.70. In terms of profitability, TEVA's ROE is +0.09%, compared to COLL's ROE of +0.16%. Regarding short-term risk, TEVA is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check COLL's competition here
PetIQ, Inc. (NASDAQ: PETQ)
TEVA vs PETQ Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TEVA's ROE is +0.09%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TEVA is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
TEVA vs AMPH Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while AMPH trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas AMPH's P/E ratio is 7.09. In terms of profitability, TEVA's ROE is +0.09%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TEVA is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AMPH's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
TEVA vs IRWD Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while IRWD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas IRWD's P/E ratio is 5.54. In terms of profitability, TEVA's ROE is +0.09%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, TEVA is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
TEVA vs EVO Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while EVO trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas EVO's P/E ratio is -2.82. In terms of profitability, TEVA's ROE is +0.09%, compared to EVO's ROE of -0.24%. Regarding short-term risk, TEVA is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
TEVA vs BDSI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TEVA's ROE is +0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TEVA is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
TEVA vs TLRY Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while TLRY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas TLRY's P/E ratio is -7.21. In terms of profitability, TEVA's ROE is +0.09%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, TEVA is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check TLRY's competition here
Evolus, Inc. (NASDAQ: EOLS)
TEVA vs EOLS Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while EOLS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas EOLS's P/E ratio is -24.04. In terms of profitability, TEVA's ROE is +0.09%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, TEVA is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
TEVA vs AQST Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while AQST trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas AQST's P/E ratio is -6.46. In terms of profitability, TEVA's ROE is +0.09%, compared to AQST's ROE of +1.91%. Regarding short-term risk, TEVA is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
TEVA vs KMDA Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while KMDA trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas KMDA's P/E ratio is 20.77. In terms of profitability, TEVA's ROE is +0.09%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TEVA is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
TEVA vs CGC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas CGC's P/E ratio is -0.58. In terms of profitability, TEVA's ROE is +0.09%, compared to CGC's ROE of -0.31%. Regarding short-term risk, TEVA is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
TEVA vs TKNO Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while TKNO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas TKNO's P/E ratio is -20.84. In terms of profitability, TEVA's ROE is +0.09%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TEVA is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
TEVA vs ALIM Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TEVA's ROE is +0.09%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TEVA is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
TEVA vs LNDC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TEVA's ROE is +0.09%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, TEVA is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check LNDC's competition here
Embecta Corp. (NASDAQ: EMBC)
TEVA vs EMBC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while EMBC trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas EMBC's P/E ratio is 1.70. In terms of profitability, TEVA's ROE is +0.09%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, TEVA is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EMBC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
TEVA vs ORGO Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ORGO trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ORGO's P/E ratio is 62.00. In terms of profitability, TEVA's ROE is +0.09%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, TEVA is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
TEVA vs TYHT Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TEVA's ROE is +0.09%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TEVA is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
TEVA vs SIGA Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while SIGA trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas SIGA's P/E ratio is 11.30. In terms of profitability, TEVA's ROE is +0.09%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TEVA is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
TEVA vs LFCR Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while LFCR trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas LFCR's P/E ratio is -4.68. In terms of profitability, TEVA's ROE is +0.09%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, TEVA is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
TEVA vs ACB Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ACB trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ACB's P/E ratio is -6.10. In terms of profitability, TEVA's ROE is +0.09%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TEVA is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ACB's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
TEVA vs REPH Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas REPH's P/E ratio is -8.04. In terms of profitability, TEVA's ROE is +0.09%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TEVA is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
TEVA vs DERM Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas DERM's P/E ratio is -17.38. In terms of profitability, TEVA's ROE is +0.09%, compared to DERM's ROE of -0.36%. Regarding short-term risk, TEVA is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
TEVA vs CRDL Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while CRDL trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas CRDL's P/E ratio is -5.05. In terms of profitability, TEVA's ROE is +0.09%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, TEVA is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
TEVA vs THTX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas THTX's P/E ratio is -28.83. In terms of profitability, TEVA's ROE is +0.09%, compared to THTX's ROE of +0.17%. Regarding short-term risk, TEVA is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
TEVA vs ASRT Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TEVA's ROE is +0.09%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TEVA is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
TEVA vs OGI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while OGI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas OGI's P/E ratio is -3.81. In terms of profitability, TEVA's ROE is +0.09%, compared to OGI's ROE of -0.07%. Regarding short-term risk, TEVA is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check OGI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
TEVA vs CPIX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while CPIX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas CPIX's P/E ratio is -19.50. In terms of profitability, TEVA's ROE is +0.09%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TEVA is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
TEVA vs SCTL Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TEVA's ROE is +0.09%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TEVA is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
TEVA vs PROC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas PROC's P/E ratio is 1.53. In terms of profitability, TEVA's ROE is +0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TEVA is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
TEVA vs OPTN Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TEVA's ROE is +0.09%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TEVA is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
TEVA vs ZOM Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TEVA's ROE is +0.09%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, TEVA is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
TEVA vs ZYBT Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ZYBT trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, TEVA's ROE is +0.09%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, TEVA is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
TEVA vs GRVI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TEVA's ROE is +0.09%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, TEVA is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
TEVA vs ZYNE Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TEVA's ROE is +0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TEVA is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
TEVA vs SSIC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TEVA's ROE is +0.09%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TEVA is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
TEVA vs VLNS Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TEVA's ROE is +0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, TEVA is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check VLNS's competition here
BGM Group Ltd. (NASDAQ: BGM)
TEVA vs BGM Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas BGM's P/E ratio is -1.04. In terms of profitability, TEVA's ROE is +0.09%, compared to BGM's ROE of -0.07%. Regarding short-term risk, TEVA is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check BGM's competition here
DURECT Corporation (NASDAQ: DRRX)
TEVA vs DRRX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TEVA's ROE is +0.09%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, TEVA is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
TEVA vs INCR Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, INCR has a market cap of 58M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while INCR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas INCR's P/E ratio is -2.26. In terms of profitability, TEVA's ROE is +0.09%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TEVA is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
TEVA vs JUPW Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TEVA's ROE is +0.09%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, TEVA is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
TEVA vs QLI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas QLI's P/E ratio is -4.92. In terms of profitability, TEVA's ROE is +0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TEVA is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
TEVA vs HEXO Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TEVA's ROE is +0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TEVA is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
TEVA vs TLPH Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while TLPH trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas TLPH's P/E ratio is -4.61. In terms of profitability, TEVA's ROE is +0.09%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, TEVA is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
TEVA vs RMTI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while RMTI trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas RMTI's P/E ratio is -6.89. In terms of profitability, TEVA's ROE is +0.09%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, TEVA is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
TEVA vs AYTU Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas AYTU's P/E ratio is -1.23. In terms of profitability, TEVA's ROE is +0.09%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, TEVA is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
TEVA vs TXMD Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas TXMD's P/E ratio is 105.45. In terms of profitability, TEVA's ROE is +0.09%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, TEVA is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
TEVA vs CYTH Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TEVA's ROE is +0.09%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TEVA is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
TEVA vs EVOK Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TEVA's ROE is +0.09%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, TEVA is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
TEVA vs BFRIW Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, TEVA's ROE is +0.09%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, TEVA is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
TEVA vs OPTH Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while OPTH trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas OPTH's P/E ratio is -18.56. In terms of profitability, TEVA's ROE is +0.09%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, TEVA is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
TEVA vs ACRX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TEVA's ROE is +0.09%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, TEVA is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
TEVA vs COSM Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas COSM's P/E ratio is -0.38. In terms of profitability, TEVA's ROE is +0.09%, compared to COSM's ROE of -0.96%. Regarding short-term risk, TEVA is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
TEVA vs AGRX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TEVA's ROE is +0.09%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TEVA is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
TEVA vs NLTX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TEVA's ROE is +0.09%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, TEVA is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
TEVA vs LCI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas LCI's P/E ratio is -0.04. In terms of profitability, TEVA's ROE is +0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TEVA is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
TEVA vs ADMP Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TEVA's ROE is +0.09%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TEVA is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
TEVA vs YCBD Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas YCBD's P/E ratio is -1.38. In terms of profitability, TEVA's ROE is +0.09%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TEVA is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
TEVA vs GELS Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas GELS's P/E ratio is -1.09. In terms of profitability, TEVA's ROE is +0.09%, compared to GELS's ROE of -0.25%. Regarding short-term risk, TEVA is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
TEVA vs MNK Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas MNK's P/E ratio is -0.44. In terms of profitability, TEVA's ROE is +0.09%, compared to MNK's ROE of -0.26%. Regarding short-term risk, TEVA is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
TEVA vs FLGC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TEVA's ROE is +0.09%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TEVA is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check FLGC's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
TEVA vs CPHI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while CPHI trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas CPHI's P/E ratio is -1.76. In terms of profitability, TEVA's ROE is +0.09%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, TEVA is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CPHI's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
TEVA vs UPC Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while UPC trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas UPC's P/E ratio is -0.69. In terms of profitability, TEVA's ROE is +0.09%, compared to UPC's ROE of -0.03%. Regarding short-term risk, TEVA is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
TEVA vs SBFM Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while SBFM trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas SBFM's P/E ratio is -0.20. In terms of profitability, TEVA's ROE is +0.09%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, TEVA is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SBFM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
TEVA vs SHPH Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while SHPH trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas SHPH's P/E ratio is -0.20. In terms of profitability, TEVA's ROE is +0.09%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, TEVA is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SHPH's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
TEVA vs PLXP Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TEVA's ROE is +0.09%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TEVA is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PLXP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
TEVA vs SNOA Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while SNOA trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas SNOA's P/E ratio is -1.22. In terms of profitability, TEVA's ROE is +0.09%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TEVA is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
TEVA vs ATNX Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TEVA's ROE is +0.09%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TEVA is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
TEVA vs PROCW Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas PROCW's P/E ratio is N/A. In terms of profitability, TEVA's ROE is +0.09%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, TEVA is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
TEVA vs RDHL Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas RDHL's P/E ratio is 0.12. In terms of profitability, TEVA's ROE is +0.09%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, TEVA is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
TEVA vs YCBD-PA Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, TEVA's ROE is +0.09%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, TEVA is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
TEVA vs CYTHW Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas CYTHW's P/E ratio is N/A. In terms of profitability, TEVA's ROE is +0.09%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, TEVA is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check CYTHW's competition here
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
TEVA vs LSDI Comparison August 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 41.2B. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, TEVA is priced at $35.36 on the NYSE, while LSDI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 12.06, whereas LSDI's P/E ratio is -0.07. In terms of profitability, TEVA's ROE is +0.09%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, TEVA is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check LSDI's competition here